Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Connors

Showing results (171-180 of 302) with videos related to

Pageof 31
Sort By:
Blood|November 11, 2017
FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapyAnja Mottok, Vindi Jurinovic, Pedro Farinha, et al.
British Journal of Haematology|March 13, 2019
Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomasFredrik Ellin, Matthew J Maurer, Line Srour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British ColumbiaGreg Hapgood, Yvonne Zheng, Laurie H Sehn, et al.
Blood|September 23, 2020
Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphomaDavid D W Twa, Derrick G Lee, King L Tan, et al.
Blood|July 14, 2019
Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphomaCiara L Freeman, Robert Kridel, Alden A Moccia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology GroupRalph M Meyer, Mary K Gospodarowicz, Joseph M Connors, et al.
Blood|August 16, 2008
Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalancesK-John J Cheung, Sohrab P Shah, Christian Steidl, et al.
Haematologica|July 14, 2018
Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVDDiego Villa, Laurie H Sehn, Christina Aquino-Parsons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2017
International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell LymphomaMatthew J Maurer, Fredrik Ellin, Line Srour, et al.
Blood|September 6, 2012
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trialKing L Tan, David W Scott, Fangxin Hong, et al.
Pageof 31

Showing results (171-180 of 302) with videos related to

Sort By:
Pageof 31
Blood|November 11, 2017
FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapyAnja Mottok, Vindi Jurinovic, Pedro Farinha, et al.
British Journal of Haematology|March 13, 2019
Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomasFredrik Ellin, Matthew J Maurer, Line Srour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British ColumbiaGreg Hapgood, Yvonne Zheng, Laurie H Sehn, et al.
Blood|September 23, 2020
Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphomaDavid D W Twa, Derrick G Lee, King L Tan, et al.
Blood|July 14, 2019
Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphomaCiara L Freeman, Robert Kridel, Alden A Moccia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology GroupRalph M Meyer, Mary K Gospodarowicz, Joseph M Connors, et al.
Blood|August 16, 2008
Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalancesK-John J Cheung, Sohrab P Shah, Christian Steidl, et al.
Haematologica|July 14, 2018
Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVDDiego Villa, Laurie H Sehn, Christina Aquino-Parsons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2017
International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell LymphomaMatthew J Maurer, Fredrik Ellin, Line Srour, et al.
Blood|September 6, 2012
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trialKing L Tan, David W Scott, Fangxin Hong, et al.
Pageof 31